RAPID MICRO BIOSYSTEMS, INC.

Rapid Micro Biosystems, Inc. entered into an underwriting agreement on May 18, 2026, for an underwritten offering of its Class A common stock and accompanying Series A and Series B warrants. The offering includes 3,581,000 shares of common stock and up to 1,463,000 pre-funded warrants, each with accompanying warrants. The combined offering price is $1.955 per unit for shares and warrants, and $1.945 per unit for pre-funded warrants and warrants. The offering is expected to close on May 20, 2026.

Rapid Micro Biosystems, Inc. announced the pricing of an underwritten offering of 3,581,000 shares of Class A common stock and accompanying Series A and Series B warrants, along with pre-funded warrants for certain investors. The combined offering price for common stock and warrants is $1.955, while for pre-funded warrants and warrants it is $1.945. Existing investor Bain Capital Life Sciences and Armistice Capital LLC are participating in the offering. Additionally, the company entered into a concurrent registered direct offering with officers and directors for 71,607 shares and accompanying warrants. The gross proceeds from both offerings are expected to be approximately $9.8 million, with potential for an additional $21.7 million if all warrants are exercised.

Rapid Micro Biosystems reported a net loss of $(14.28) million for Q1 2026, a significant increase from $(11.26) million in Q1 2025. Total revenue grew to $8.00 million from $7.21 million year-over-year, driven by product revenue growth but offset by a decline in service revenue. The company also experienced a substantial increase in net cash used in operating activities, reaching $(15.06) million, and a decrease in cash and cash equivalents to $13.82 million.

Rapid Micro Biosystems reported an 11.1% increase in total revenue to $8.0 million for the first quarter of 2026, driven by strong product revenue growth of 36.0% and a 27.7% rise in recurring revenue. The company placed 6 Growth Direct systems, doubling the placements from the prior year, and saw significant improvements in product and consumable gross margins. Despite these operational gains, the net loss widened to $14.3 million, or $0.31 per share, and cash reserves decreased. The company reaffirmed its full year 2026 revenue and system placement guidance.

Rapid Micro Biosystems reported first quarter 2026 total revenue of $8.0 million, an 11.1% increase year-over-year, driven by strong product and consumable revenue growth. The company placed 6 Growth Direct systems, doubling placements from the prior year, and advanced its strategic collaboration with MilliporeSigma. Despite operational growth and reaffirmed full-year revenue and system placement guidance, the company reported an increased net loss of $14.3 million for the quarter.

Rapid Micro Biosystems, Inc. announced it will release its first quarter 2026 financial results after the market close on Wednesday, May 13, 2026. Following the release, the company's management team will host a webcast conference call at 4:30 p.m. ET on the same day. The live audio webcast will be accessible on the Company's website, with an archived replay available after the event.